Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

August 25, 2018

Dallas, Texas

Continuing Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity has been approved for AMA PRA Category 1 Credits™.

ACCMEMaintenance of Certification
ABIM MOC Successful completion of this CME activity enables a participant to earn MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.

Imedex®, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. In support of improving patient care, NACCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Who Should Attend
This educational activity is specifically designed for gastroenterologists, and other healthcare professionals (physicians-in-training, nurses, pharmacists, physician assistants, nurse practitioners, etc.) involved and/or interested in the therapeutic management of patients with IBD.


After successful completion of this activity, participants will be better able to:

  • Identify the safety-efficacy profiles and therapeutic potential of current and novel targeted therapies in IBD
  • Recognize how integration of relevant clinical trial data into clinical practice has the potential to enhance outcomes in patients with IBD
  • Integrate health maintenance guidelines such as vaccination, cancer screening as a tool for providing enhanced quality care for patients with IBD
  • Define a rational use of biologics during and after pregnancy and analyze pregnancy outcomes based on the treatment strategy
  • Analyze the emerging role of biosimilars in IBD pertaining to their regulatory approval pathway, extrapolation and interchangeability
  • Identify strategies to guide the transition of care from pediatric to adult patients with IBD